Hepatitis B Vaccination and Antibody Response
Yes, after successful hepatitis B vaccination, you should have a positive hepatitis B surface antibody (anti-HBs) with a protective concentration of ≥10 mIU/mL when tested 1-2 months after completing the vaccine series. 1
Defining Successful Vaccination
Persons with anti-HBs concentrations of ≥10 mIU/mL after the primary vaccine series are considered immune and successfully vaccinated. 1 This threshold represents the protective level that indicates adequate immune response to the vaccine.
Testing Timing and Methodology
Testing should be performed 1-2 months after administration of the final dose of the vaccine series using a quantitative method that allows determination of protective anti-HBs concentrations (≥10 mIU/mL), such as enzyme-linked immunosorbent assay (ELISA). 1
Testing at this specific timeframe is critical because it captures peak antibody response before natural decline begins. 1
Who Should Be Tested After Vaccination
Not everyone requires postvaccination serologic testing. The Advisory Committee on Immunization Practices (ACIP) recommends testing for specific high-risk groups: 1
- Healthcare personnel and public safety workers at risk for blood or body fluid exposure 1, 2
- Hemodialysis patients and persons who might require outpatient hemodialysis 1
- HIV-infected persons and other immunocompromised persons (e.g., hematopoietic stem-cell transplant recipients or persons receiving chemotherapy) 1
- Sex partners of HBsAg-positive persons 1
Expected Response Rates
Approximately 95% of healthy-term infants and immunocompetent adults develop protective anti-HBs responses after completing the hepatitis B vaccination series. 2 However, 5-10% of vaccinated individuals may not achieve protective antibody levels after the initial series. 1
Management of Non-Responders
Persons found to have anti-HBs concentrations <10 mIU/mL after the primary vaccine series should be revaccinated. 1 The approach is:
- Administer all doses in a second complete series on an appropriate schedule 1
- Perform anti-HBs testing 1-2 months after the final dose of the second series 1
- Persons who do not achieve protective anti-HBs levels after revaccination should be tested for HBsAg to rule out chronic HBV infection 1
Long-Term Antibody Persistence
A critical caveat: Immunocompetent persons with documented protective anti-HBs levels have long-term protection and do not need further periodic testing to assess anti-HBs levels, even if antibody levels decline below 10 mIU/mL over time. 1
This is because:
- Vaccine-induced immunologic memory persists for at least 5-12 years or longer, providing ongoing protection independent of measurable antibody levels 3
- Memory B lymphocytes capable of producing anti-HBs remain present even when circulating antibody declines 3
- Studies show very few clinically significant breakthrough infections in vaccinees who lose detectable antibody but were initially responders 3
Exception for Immunocompromised Patients
Immunocompromised persons might need annual testing to assess anti-HBs concentrations because their immunologic memory may not be as durable. 1
Assay Variability
Anti-HBs levels of ≥10 mIU/mL are generally considered seroprotective; however, different assays have different cutoff values. 1 Always refer to the package insert of the specific test used for determination of actual anti-HBs antibody levels, as reported levels might vary depending on the assay. 1
Antibody Decline Over Time
While antibody levels naturally decline after vaccination, this does not indicate loss of protection in immunocompetent individuals. Studies show:
- Mean antibody titers decrease predictably over time, with levels potentially declining below protective thresholds at 37 months and to seronegativity at 75 months 4
- Despite declining antibody levels, routine booster vaccination is not generally recommended for persons with normal immune status who were vaccinated as infants, children, adolescents, or adults 1